PATENT CLAIM ANALYSIS

Application Number: 15861047
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-10
Patent Classification: ["424", "134100"]

Abstract:
Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.

Claim (Index 67):
A method of treating mesothelioma, comprising administering to a subject in need thereof 5-20 mg/kg of an FGFR1 ECD fusion molecule, wherein at least a portion of the cells of the subject's mesothelioma were determined to overexpress FGF2 prior to the administration, and wherein the FGFR1 ECD fusion molecule comprises an amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 86.0
- Lexical Diversity: 2.42553
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14357336', '14890047', '13296168', '13509068', '13612044']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.760676973872715
- 35 USC 102 Novelty (BERT): 0.590800884731248
- Combined Prediction Score: 0.7436893649585684
- Mean Citation Score: 457.58438
- Max Citation Score: 581.17145
- Similarity Product: 417.7402927560002

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test